What You Should Know
- Nutrition support is often introduced early, with a focus on protein to help patients maintain strength and overall health during treatment, says Dr. Karyn Goodman of Mount Sinai.
- Digestive issues frequently contribute to cancer-related weight loss because the pancreas produces enzymes needed to break down food; many patients develop exocrine pancreatic insufficiency (EPI), when the pancreas doesn’t make enough of those enzymes.
- Research shows 72% of patients with advanced pancreatic cancer experience EPI, making pancreatic enzyme replacement therapy (PERT) an important tool to improve digestion and reduce symptoms such as diarrhea, gas, and bloating. Treating EPI may also improve nutrition and overall survival.
- With newer treatments such as daraxonrasib (Rasonque) helping patients live longer, good nutrition matters even more for maintaining strength during treatment.
“One of the most common symptoms of pancreatic cancer is weight loss. So this could have been going on even for months before they’re diagnosed,” Dr. Karyn Goodman, Co-Director of the Center of Excellence for Pancreatic Cancer at Mount Sinai and Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology at the Icahn School of Medicine at Mount Sinai, tells SurvivorNet.
Read MoreThe Maldigestion Problem
Part of that weight loss isn’t anorexia (loss of appetite) or cachexia (the muscle and weight wasting caused by cancer) alone. It’s maldigestion, when the body can’t properly break down and absorb food. “We also have another major issue because the pancreas is involved in digestion,” Dr. Goodman says.“It makes the enzymes that help to break down foods as they go through the intestines, in particular fat. That can be a reason why they’re losing weight as well. They’re not digesting, and they’re not getting enough of the fats from their food.”
Research published in the United European Gastroenterology Journal found that nearly three-quarters (72%) of patients with advanced pancreatic cancer experience exocrine pancreatic insufficiency (EPI), a condition in which the pancreas doesn’t make enough digestive enzymes.
Enzyme Replacement, Started Early
“We often start patients on a medication that is basically an enzyme replacement for the pancreatic enzyme,” Dr. Goodman says.
“We use that early on if the patients are losing weight and they take it with food, and that hopefully will help to improve their ability to digest food. And then also reduces some of the other side effects like diarrhea and gas and bloating that can happen when they’re not digesting well.”
“This is something that we recommend for many of our patients with pancreatic cancer,” she adds.
Pancreatic enzyme replacement therapy (PERT) for patients with pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and EPI is a long-standing recommendation of the National Comprehensive Cancer Network (NCCN), whose guidelines are widely used by cancer doctors.
Research published in the medical journal The Oncologist shows that treating exocrine pancreatic insufficiency (EPI) leads to “improvements in nutrition and overall survival.”
For clinicians, the takeaway is that prescribing enzymes isn’t enough. Dosing and symptom response need follow-up.
Why Nutrition Matters More Now
Nutrition carries extra weight as systemic options improve.
Daraxonrasib (Rasonque) is indicated for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
In the phase 3 RASolute 302 trial, it demonstrated a median overall survival of 13.2 months versus 6.7 months withchemotherapy. Notably, the approved indication is not restricted by RAS genotype, meaning patients don’t need a specific RAS gene mutation to qualify.
“This is by far the most effective treatment ever to be developed for pancreatic cancer,” says Dr. Peter Hosein, Associate Director for Clinical Research at the Pancreatic Cancer Research Institute at Sylvester Comprehensive Cancer Center.
“With other ongoing trials, it is conceivable that in the future, we will recommend this pill for someone with newly diagnosed pancreatic cancer rather than chemotherapy infusions, which have been the standard for decades.”
The nutrition connection may go both ways. Dr. Hosein told National Geographic that some patients on the drug (at Sylvester) also saw declining cancer markers, renewed appetite, and weight gain.
As patients remain on effective therapies longer, maintaining good nutrition and digestive health can help preserve the strength and overall well-being needed to navigate future treatment options.
Learn more about SurvivorNet's rigorous medical review process.
